Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management.
Olsson KM, Corte TJ, Kamp JC, Montani D, Nathan SD, Neubert L, Price LC, Kiely DG.
Lancet Respir Med. 2023 Sep;11(9):820-835. doi: 10.1016/S2213-2600(23)00259-X. Epub 2023 Aug 14.
Pulmonary hypertension phenotypes in patients with systemic sclerosis.
Haque A, Kiely DG, Kovacs G, Thompson AAR, Condliffe R.
Eur Respir Rev. 2021 Aug 17;30(161):210053. doi: 10.1183/16000617.0053-2021. Print 2021 Sep 30.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Born E, Lipskaia L, Breau M, Houssaini A, Beaulieu D, Marcos E, Pierre R, Do Cruzeiro M, Lefevre M, Derumeaux G, Bulavin DV, Delcroix M, Quarck R, Reen V, Gil J, Bernard D, Flaman JM, Adnot S, Abid S.
Circulation. 2023 Feb 21;147(8):650-666. doi: 10.1161/CIRCULATIONAHA.122.058794. Epub 2022 Dec 14.
Wnt7a deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension.
Chakraborty A, Nathan A, Orcholski M, Agarwal S, Shamskhou EA, Auer N, Mitra A, Guardado ES, Swaminathan G, Condon DF, Yu J, McCarra M, Juul NH, Mallory A, Guzman-Hernandez RA, Yuan K, Rojas V, Crossno JT, Yung LM, Yu PB, Spencer T, Winn RA, Frump A, Karoor V, Lahm T, Hedlin H, Fineman JR, Lafyatis R, Knutsen CNF, Alvira CM, Cornfield DN, de Jesus Perez VA.
Eur Respir J. 2023 Jun 8;61(6):2201625. doi: 10.1183/13993003.01625-2022. Print 2023 Jun.
Management of Pulmonary Hypertension Associated with Chronic Lung Disease.
Blanco I, Hernández-González F, García A, Torres-Castro R, Barberà JA.
Semin Respir Crit Care Med. 2023 Dec;44(6):826-839. doi: 10.1055/s-0043-1770121. Epub 2023 Jul 24.
Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1.
Tang BL, Liu Y, Zhang JL, Lu ML, Wang HX.
Biomed Pharmacother. 2023 Aug;164:114920. doi: 10.1016/j.biopha.2023.114920. Epub 2023 May 20.
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
Moinzadeh P, Bonella F, Oberste M, Weliwitage J, Blank N, Riemekasten G, Müller-Ladner U, Henes J, Siegert E, Günther C, Kötter I, Pfeiffer C, Schmalzing M, Zeidler G, Korsten P, Susok L, Juche A, Worm M, Jandova I, Ehrchen J, Sunderkötter C, Keyßer G, Ramming A, Schmeiser T, Kreuter A, Lorenz HM, Hunzelmann N, Kreuter M.
Chest. 2024 Jan;165(1):132-145. doi: 10.1016/j.chest.2023.08.013. Epub 2023 Aug 13.
Recent advances in the management of pulmonary hypertension with interstitial lung disease.
Waxman AB, Elia D, Adir Y, Humbert M, Harari S.
Eur Respir Rev. 2022 Jul 12;31(165):210220. doi: 10.1183/16000617.0220-2021. Print 2022 Sep 30.
Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD.
Piccari L, Blanco I, Torralba Y, Arismendi E, Gistau C, Ramírez A, Gimeno-Santos E, Roca J, Burgos F, Rodríguez-Roisín R, Barberà JA.
Eur Respir J. 2023 Jul 20;62(1):2300463. doi: 10.1183/13993003.00463-2023. Print 2023 Jul.
Pulmonary hypertension in parenchymal lung disease.
Ruggiero RM, Bartolome S, Torres F.
Heart Fail Clin. 2012 Jul;8(3):461-74. doi: 10.1016/j.hfc.2012.04.010.
